(Q73901933)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856536%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856536%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

P Pauciullo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856536%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

C Borgnino

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856536%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

R Paoletti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856536%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

M Mariani

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856536%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

M Mancini

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856536%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 June 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856536%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856536%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

150

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856536%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856536%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

429-436

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856536%20AND%20SRC:MED&resulttype=core&format=json

The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholester

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

The emerging role of statins in the prevention of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Triglycerides as a risk factor for coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Triglycerides are more important in atherosclerosis than epidemiology has suggested

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Currently available hypolipidaemic drugs and future therapeutic developments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Rhabdomyolysis associated with simvastatin-gemfibrozil therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

High-dose fluvastatin and bezafibratecombination treatment for heterozygous familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Pharmacokinetics of the combination of fluvastatin and gemfibrozil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Fluvastatin: a review of its use in lipid disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Lovastatin decreases coenzyme Q levels in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Adverse effects of drugs on muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900379-8

10.1016/S0021-9150(00)00379-8

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856536%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference